Corporate News
2024
Statement re: Silicon Valley Bank
13 March 2023
Oxford, UK. GENinCode Plc (AIM: GENI) is aware of media reports indicating the closure of Silicon Valley Bank (“SVB”). The Company does not hold any cash at SVB and does not have a banking relationship with SVB.
For more information visit www.genincode.com
Enquiries:
| GENinCode Plc | www.genincode.com or via Walbrook PR | ||
| Matthew Walls, CEO | |||
| Paul Foulger, CFO | |||
| Stifel Nicolaus Europe Limited (Nomad and Joint Broker) | Tel: +44 (0)20 7710 7600 | ||
| Alex Price / Ben Maddison / Richard Short | |||
| Cenkos Securities Plc (Joint Broker) | Tel: +44 (0)20 7397 8900 | ||
| Giles Balleny | |||
| Dale Bellis / Michael Johnson (Sales) | |||
| Walbrook PR Limited Anna Dunphy / Paul McManus / Louis Ashe-Jepson | Tel: 020 7933 8780 or [email protected] | ||
About GENinCode:
GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.
GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.
GENinCode tests and technology provide physicians and patients with globally leading preventative care and treatment strategies. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to prevent cardiovascular disease.
2023
Statement re: Silicon Valley Bank
13 March 2023
Oxford, UK. GENinCode Plc (AIM: GENI) is aware of media reports indicating the closure of Silicon Valley Bank (“SVB”). The Company does not hold any cash at SVB and does not have a banking relationship with SVB.
For more information visit www.genincode.com
Enquiries:
| GENinCode Plc | www.genincode.com or via Walbrook PR | ||
| Matthew Walls, CEO | |||
| Paul Foulger, CFO | |||
| Stifel Nicolaus Europe Limited (Nomad and Joint Broker) | Tel: +44 (0)20 7710 7600 | ||
| Alex Price / Ben Maddison / Richard Short | |||
| Cenkos Securities Plc (Joint Broker) | Tel: +44 (0)20 7397 8900 | ||
| Giles Balleny | |||
| Dale Bellis / Michael Johnson (Sales) | |||
| Walbrook PR Limited Anna Dunphy / Paul McManus / Louis Ashe-Jepson | Tel: 020 7933 8780 or [email protected] | ||
About GENinCode:
GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.
GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.
GENinCode tests and technology provide physicians and patients with globally leading preventative care and treatment strategies. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to prevent cardiovascular disease.
2022
Statement re: Silicon Valley Bank
13 March 2023
Oxford, UK. GENinCode Plc (AIM: GENI) is aware of media reports indicating the closure of Silicon Valley Bank (“SVB”). The Company does not hold any cash at SVB and does not have a banking relationship with SVB.
For more information visit www.genincode.com
Enquiries:
| GENinCode Plc | www.genincode.com or via Walbrook PR | ||
| Matthew Walls, CEO | |||
| Paul Foulger, CFO | |||
| Stifel Nicolaus Europe Limited (Nomad and Joint Broker) | Tel: +44 (0)20 7710 7600 | ||
| Alex Price / Ben Maddison / Richard Short | |||
| Cenkos Securities Plc (Joint Broker) | Tel: +44 (0)20 7397 8900 | ||
| Giles Balleny | |||
| Dale Bellis / Michael Johnson (Sales) | |||
| Walbrook PR Limited Anna Dunphy / Paul McManus / Louis Ashe-Jepson | Tel: 020 7933 8780 or [email protected] | ||
About GENinCode:
GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.
GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.
GENinCode tests and technology provide physicians and patients with globally leading preventative care and treatment strategies. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to prevent cardiovascular disease.
2021
Statement re: Silicon Valley Bank
13 March 2023
Oxford, UK. GENinCode Plc (AIM: GENI) is aware of media reports indicating the closure of Silicon Valley Bank (“SVB”). The Company does not hold any cash at SVB and does not have a banking relationship with SVB.
For more information visit www.genincode.com
Enquiries:
| GENinCode Plc | www.genincode.com or via Walbrook PR | ||
| Matthew Walls, CEO | |||
| Paul Foulger, CFO | |||
| Stifel Nicolaus Europe Limited (Nomad and Joint Broker) | Tel: +44 (0)20 7710 7600 | ||
| Alex Price / Ben Maddison / Richard Short | |||
| Cenkos Securities Plc (Joint Broker) | Tel: +44 (0)20 7397 8900 | ||
| Giles Balleny | |||
| Dale Bellis / Michael Johnson (Sales) | |||
| Walbrook PR Limited Anna Dunphy / Paul McManus / Louis Ashe-Jepson | Tel: 020 7933 8780 or [email protected] | ||
About GENinCode:
GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.
GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.
GENinCode tests and technology provide physicians and patients with globally leading preventative care and treatment strategies. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to prevent cardiovascular disease.